ATE538784T1 - Verfahren zur behandlung von substanzbedingten erkrankungen - Google Patents
Verfahren zur behandlung von substanzbedingten erkrankungenInfo
- Publication number
- ATE538784T1 ATE538784T1 AT05775692T AT05775692T ATE538784T1 AT E538784 T1 ATE538784 T1 AT E538784T1 AT 05775692 T AT05775692 T AT 05775692T AT 05775692 T AT05775692 T AT 05775692T AT E538784 T1 ATE538784 T1 AT E538784T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- phenyl
- alkyl
- group
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2005/026439 WO2007018496A1 (en) | 2005-07-26 | 2005-07-26 | Methods for treating substance-related disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE538784T1 true ATE538784T1 (de) | 2012-01-15 |
Family
ID=35064669
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05775692T ATE538784T1 (de) | 2005-07-26 | 2005-07-26 | Verfahren zur behandlung von substanzbedingten erkrankungen |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1928451B1 (de) |
JP (1) | JP5094720B2 (de) |
KR (1) | KR101199499B1 (de) |
CN (1) | CN101272776B (de) |
AT (1) | ATE538784T1 (de) |
AU (1) | AU2005335241B9 (de) |
BR (1) | BRPI0520451A2 (de) |
CA (1) | CA2616721C (de) |
EA (1) | EA019935B1 (de) |
ES (1) | ES2385087T3 (de) |
IL (1) | IL189003A0 (de) |
NO (1) | NO20080877L (de) |
WO (1) | WO2007018496A1 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2417077C2 (ru) | 2005-06-08 | 2011-04-27 | Ск Холдингз Ко., Лтд. | Способ лечения чрезмерной дневной сонливости (варианты) |
WO2011005473A2 (en) | 2009-06-22 | 2011-01-13 | Shionogi Pharma, Inc. | Methods for treating or preventing fatigue |
US8232315B2 (en) * | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
CN102762201B (zh) | 2009-11-06 | 2013-12-18 | 爱思开生物制药株式会社 | 注意力缺陷/多动症的治疗方法 |
KR101783633B1 (ko) | 2009-11-06 | 2017-10-10 | 에스케이바이오팜 주식회사 | 섬유근육통 증후군의 치료 방법 |
US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
CA2905457A1 (en) | 2013-03-13 | 2014-10-09 | Aerial Biopharma, Llc | Treatment of cataplexy |
EP3021838B1 (de) | 2013-07-18 | 2020-05-27 | Jazz Pharmaceuticals Ireland Limited | Behandlung von adipositas |
US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
AU2018278332B2 (en) | 2017-06-02 | 2022-05-19 | Jazz Pharmaceuticals Ireland Limited | Methods and compositions for treating excessive sleepiness |
WO2020262317A1 (ja) * | 2019-06-27 | 2020-12-30 | Numan Labo合同会社 | 認知症の治療及び予防薬 |
US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
IL157588A0 (en) * | 2001-02-27 | 2004-03-28 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing or treating psychotic disorders |
MXPA03007719A (es) * | 2001-02-27 | 2004-11-12 | Johnson & Johnson | Compuestos de carbamato para su uso en la prevencion o el tratamiento de transtornos neurodegenerativos. |
ATE361745T1 (de) * | 2001-02-27 | 2007-06-15 | Ortho Mcneil Pharm Inc | Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen |
EP1368021B1 (de) * | 2001-02-27 | 2007-11-14 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen |
US20070021500A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods for neuroprotection |
-
2005
- 2005-07-26 JP JP2008523847A patent/JP5094720B2/ja active Active
- 2005-07-26 CN CN200580051664XA patent/CN101272776B/zh active Active
- 2005-07-26 CA CA2616721A patent/CA2616721C/en active Active
- 2005-07-26 KR KR1020087004533A patent/KR101199499B1/ko active IP Right Grant
- 2005-07-26 EP EP05775692A patent/EP1928451B1/de active Active
- 2005-07-26 EA EA200800422A patent/EA019935B1/ru not_active IP Right Cessation
- 2005-07-26 AT AT05775692T patent/ATE538784T1/de active
- 2005-07-26 AU AU2005335241A patent/AU2005335241B9/en not_active Ceased
- 2005-07-26 BR BRPI0520451-8A patent/BRPI0520451A2/pt not_active Application Discontinuation
- 2005-07-26 WO PCT/US2005/026439 patent/WO2007018496A1/en active Application Filing
- 2005-07-26 ES ES05775692T patent/ES2385087T3/es active Active
-
2008
- 2008-01-24 IL IL189003A patent/IL189003A0/en unknown
- 2008-02-19 NO NO20080877A patent/NO20080877L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1928451A1 (de) | 2008-06-11 |
KR20080037055A (ko) | 2008-04-29 |
KR101199499B1 (ko) | 2012-11-09 |
EA200800422A1 (ru) | 2008-10-30 |
EP1928451B1 (de) | 2011-12-28 |
JP2009502914A (ja) | 2009-01-29 |
WO2007018496A1 (en) | 2007-02-15 |
EA019935B1 (ru) | 2014-07-30 |
JP5094720B2 (ja) | 2012-12-12 |
ES2385087T3 (es) | 2012-07-18 |
CA2616721C (en) | 2014-01-21 |
BRPI0520451A2 (pt) | 2009-05-12 |
AU2005335241B2 (en) | 2012-11-15 |
CA2616721A1 (en) | 2007-02-15 |
AU2005335241B9 (en) | 2012-12-20 |
AU2005335241A1 (en) | 2007-02-15 |
CN101272776B (zh) | 2012-10-03 |
NO20080877L (no) | 2008-02-19 |
IL189003A0 (en) | 2008-11-03 |
CN101272776A (zh) | 2008-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20080877L (no) | Fremgangsmater for behandling av substansrelaterte forstyrrelser | |
NO20071921L (no) | Fremgangsmater for behandling av epileptogenese og epilepsi | |
EA200800294A1 (ru) | Способы нейропротекции | |
EA200800295A1 (ru) | Способы лечения эпилептогенеза | |
YU67703A (sh) | Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja | |
MY138156A (en) | Carbamate compounds for use in preventing or treating neurodegenerative disorders | |
DE60210976D1 (de) | Carbamatverbindungen zur verwendung bei der prävention oder behandlung der bipolaren erkrankung | |
ATE378046T1 (de) | Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen | |
DE60210960D1 (de) | Carbamat-verbindungen zur prävention oder behandlung von angstzuständen | |
MX2009004553A (es) | Metodos para el tratamiento de trastornos cocleares y vestibulares. | |
RS67503A (en) | Carbamate compounds for use in preventing of treating psychotic disorders | |
MY149385A (en) | Methods for treating substance-related disorders | |
DE60232796D1 (de) | Carbamate verbindungen zur vorbeugung oder behandlung von neuropathischen schmerzen | |
MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
TW200701978A (en) | Methods of treating epileptogenesis and epilepsy |